10376 studies found for:    NCI
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Completed Imatinib Mesylate in Treating Patients With Advanced Cancer and Kidney Failure
Conditions: Malignant Neoplasm;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: imatinib mesylate;   Other: laboratory biomarker analysis;   Other: pharmacological study
2 Suspended Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Conditions: Adult Angiosarcoma;   Recurrent Adult Soft Tissue Sarcoma;   Stage III Adult Soft Tissue Sarcoma;   Stage IV Adult Soft Tissue Sarcoma
Interventions: Biological: trebananib;   Other: laboratory biomarker analysis
3 Terminated Erlotinib in Treating Patients With Stage I-IIIA Non-Small Cell Lung Cancer Undergoing Surgical Resection
Conditions: Stage IA Non-small Cell Lung Cancer;   Stage IB Non-small Cell Lung Cancer;   Stage IIA Non-small Cell Lung Cancer;   Stage IIB Non-small Cell Lung Cancer;   Stage IIIA Non-small Cell Lung Cancer
Interventions: Drug: erlotinib hydrochloride;   Procedure: therapeutic endoscopic surgery;   Other: laboratory biomarker analysis
4 Active, not recruiting Cixutumumab and Temsirolimus in Treating Patients With Locally Advanced or Metastatic Cancer
Condition: Malignant Neoplasm
Interventions: Drug: cixutumumab;   Drug: temsirolimus;   Other: laboratory biomarker analysis;   Other: pharmacological study
5 Terminated
Has Results
Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic Colorectal Cancer That Progressed During First-Line Therapy
Conditions: Recurrent Colon Cancer;   Recurrent Rectal Cancer;   Stage IVA Colon Cancer;   Stage IVA Rectal Cancer;   Stage IVB Colon Cancer;   Stage IVB Rectal Cancer
Interventions: Drug: irinotecan hydrochloride;   Drug: leucovorin calcium;   Drug: fluorouracil;   Biological: cetuximab;   Biological: bevacizumab
6 Completed A Study of RO4929097 in Patients With Advanced Renal Cell Carcinoma That Have Failed Vascular Endothelial Growth Factor (VEGF)/Vascular Endothelial Growth Factor Receptor (VEGFR) Therapy
Conditions: Clear Cell Renal Cell Carcinoma;   Recurrent Renal Cell Cancer;   Stage IV Renal Cell Cancer
Interventions: Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097;   Other: laboratory biomarker analysis
7 Completed UMCC 2003-064 Resveratrol in Preventing Cancer in Healthy Participants
Condition: Unspecified Adult Solid Tumor, Protocol Specific
Intervention: Drug: resveratrol
8 Completed Combination Chemotherapy and Imatinib Mesylate in Treating Children With Relapsed Acute Lymphoblastic Leukemia
Conditions: L1 Childhood Acute Lymphoblastic Leukemia;   L2 Childhood Acute Lymphoblastic Leukemia;   Non-T, Non-B Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Lymphoblastic Leukemia;   T-cell Childhood Acute Lymphoblastic Leukemia
Interventions: Drug: cytarabine;   Drug: methotrexate;   Drug: vincristine sulfate;   Drug: prednisone;   Drug: pegaspargase;   Drug: doxorubicin hydrochloride;   Drug: imatinib mesylate;   Drug: cyclophosphamide;   Drug: etoposide;   Biological: filgrastim;   Drug: leucovorin calcium;   Drug: asparaginase;   Drug: therapeutic hydrocortisone
9 Completed Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma
Condition: Melanoma (Skin)
Interventions: Biological: aldesleukin;   Biological: fowlpox virus vaccine vector;   Biological: gp100 antigen
10 Terminated SJG-136 in Treating Patients With Relapsed or Refractory Acute Leukemia, Myelodysplastic Syndromes, Blastic Phase Chronic Myelogenous Leukemia, or Chronic Lymphocytic Leukemia
Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Blastic Phase Chronic Myelogenous Leukemia;   de Novo Myelodysplastic Syndromes;   Previously Treated Myelodysplastic Syndromes;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Refractory Chronic Lymphocytic Leukemia;   Relapsing Chronic Myelogenous Leukemia;   Secondary Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndromes
Intervention: Drug: SJG-136
11 Completed Sorafenib, Cetuximab, and Irinotecan in Treating Patients With Advanced or Metastatic Colorectal Cancer
Conditions: Recurrent Colon Cancer;   Recurrent Rectal Cancer;   Stage III Colon Cancer;   Stage III Rectal Cancer;   Stage IV Colon Cancer;   Stage IV Rectal Cancer
Interventions: Drug: sorafenib tosylate;   Drug: cetuximab;   Drug: irinotecan hydrochloride
12 Completed
Has Results
Carboxyamidotriazole in Treating Patients With Stage III or Stage IV Non-small Cell Lung Cancer
Conditions: Stage IIIA Non-small Cell Lung Cancer;   Stage IIIB Non-small Cell Lung Cancer;   Stage IV Non-small Cell Lung Cancer
Interventions: Drug: carboxyamidotriazole;   Other: placebo;   Procedure: quality-of-life assessment;   Other: laboratory biomarker analysis
13 Recruiting Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Conditions: Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia;   Untreated Adult Acute Lymphoblastic Leukemia
Interventions: Biological: alemtuzumab;   Drug: dasatinib;   Drug: daunorubicin hydrochloride;   Drug: fludarabine phosphate;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: autologous hematopoietic stem cell transplantation;   Procedure: in vitro-treated peripheral blood stem cell transplantation;   Drug: dexamethasone;   Drug: cyclophosphamide;   Biological: filgrastim;   Biological: pegfilgrastim;   Drug: methotrexate;   Drug: leucovorin calcium;   Drug: melphalan;   Drug: tacrolimus;   Drug: etoposide phosphate;   Drug: cytarabine;   Drug: mercaptopurine;   Drug: vincristine sulfate;   Other: pharmacological study;   Other: laboratory biomarker analysis
14 Completed Chemotherapy With or Without Trastuzumab in Treating Patients With Metastatic Osteosarcoma
Condition: Metastatic Osteosarcoma
Interventions: Drug: doxorubicin hydrochloride;   Drug: cisplatin;   Drug: methotrexate;   Drug: leucovorin calcium;   Biological: filgrastim;   Procedure: therapeutic conventional surgery;   Radiation: radiation therapy;   Drug: etoposide;   Drug: ifosfamide;   Biological: trastuzumab;   Other: laboratory biomarker analysis
15 Recruiting Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer
Conditions: Endometrial Adenocarcinoma;   Endometrial Adenosquamous Cell Carcinoma;   Endometrial Clear Cell Carcinoma;   Endometrial Papillary Serous Carcinoma;   Recurrent Endometrial Carcinoma;   Stage IIIA Endometrial Carcinoma;   Stage IIIB Endometrial Carcinoma;   Stage IIIC Endometrial Carcinoma;   Stage IVA Endometrial Carcinoma;   Stage IVB Endometrial Carcinoma
Interventions: Drug: dasatinib;   Drug: paclitaxel;   Drug: carboplatin;   Other: laboratory biomarker analysis
16 Completed Isolated Hepatic Perfusion With Melphalan Followed by Combination Chemotherapy in Treating Patients With Unresectable Liver Metastases From Colorectal Cancer
Conditions: Colorectal Cancer;   Metastatic Cancer
Interventions: Drug: FOLFOX regimen;   Drug: fluorouracil;   Drug: isolated perfusion;   Drug: leucovorin calcium;   Drug: melphalan;   Drug: oxaliplatin
17 Active, not recruiting
Has Results
Sorafenib in Treating Patients With Malignant Gastrointestinal Stromal Tumor That Progressed During or After Previous Treatment With Imatinib Mesylate and Sunitinib Malate
Condition: Gastrointestinal Stromal Tumor
Intervention: Drug: sorafenib tosylate
18 Active, not recruiting Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma
Conditions: Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   B-cell Adult Acute Lymphoblastic Leukemia;   B-cell Chronic Lymphocytic Leukemia;   Cutaneous B-cell Non-Hodgkin Lymphoma;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Hepatosplenic T-cell Lymphoma;   Intraocular Lymphoma;   Nodal Marginal Zone B-cell Lymphoma;   Noncutaneous Extranodal Lymphoma;   Peripheral T-cell Lymphoma;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Refractory Hairy Cell Leukemia;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   T-cell Adult Acute Lymphoblastic Leukemia;   T-cell Large Granular Lymphocyte Leukemia;   Testicular Lymphoma;   Waldenström Macroglobulinemia
Interventions: Drug: Akt inhibitor MK2206;   Other: laboratory biomarker analysis
19 Completed Bortezomib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors
Condition: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: bortezomib;   Drug: carboplatin;   Drug: etoposide;   Other: laboratory biomarker analysis;   Other: pharmacological study
20 Completed Bevacizumab and Cetuximab With or Without Irinotecan in Treating Patients With Irinotecan-Refractory Metastatic Colorectal Cancer
Conditions: Recurrent Colon Cancer;   Recurrent Rectal Cancer;   Stage IVA Colon Cancer;   Stage IVA Rectal Cancer;   Stage IVB Colon Cancer;   Stage IVB Rectal Cancer
Interventions: Biological: cetuximab;   Biological: bevacizumab;   Drug: irinotecan hydrochloride;   Other: laboratory biomarker analysis

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years